Review explores whether metformin could help treat ALS and other neurodegenerative diseases
Original source
Metformin in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Population inferred from the title and abstract by Compass.
A review examines metformin as a possible treatment for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). It discusses evidence that metformin may affect metabolic, mitochondrial and inflammatory pathways involved in these conditions.
Why this matters
Metformin is already widely used for type 2 diabetes and is being considered for possible repurposing in neurodegenerative disease. However, this review does not show that metformin treats or slows ALS, so it does not currently change treatment decisions.
Limitations and context
This is a review of preclinical and clinical studies, not a new clinical trial. The article presents metformin as a candidate for future development, and further research is needed to establish whether it is safe and effective specifically for ALS.